Tag - DXB

Developments

Dimerix acquires Phase 2-ready asset for acute kidney injury

Dimerix (ASX: DXB) has announced that it has acquired DMX-652 for all indications from closely held Mission Therapeutics, expanding its pipeline in rare kidney disease. DMX-652 is a novel first and best-in-class...

July 17, 2026

Feature

CKD patients opt to stay on Dimerix drug after trial

By Len Zehr Forty-five per cent of patients in Dimerix’s (ASX:DXB) successful Phase 2a trial in chronic kidney disease (CKD), on advice from their physician, applied for and were granted access to remain on DMX-200...

August 8, 2017

Tag - DXB

Dimerix acquires Phase 2-ready asset for acute kidney injury

CKD patients opt to stay on Dimerix drug after trial

Subscribe